Sulfur burps are accompanied by severe abdominal pain, nausea, vomiting, or unexpected weight loss
Sobo approaches weight loss as long-term metabolic care
Novo Nordisk came to an agreement with the company to offer various doses of the GLP-1 medication for DTC customers
Potential clinical implications and challenges with the new obesity pharmacotherapies A new era in obesity management Tirzepatide has received FDA and EMA approval for chronic weight management and results in 20% mean WL in people without T2D
this effect is linked to several mechanisms, including: triggering the release of leptin and peptide YY to signal a sensation of fullness and satiety 29 triggering the secretion of GLP-1 to increase feelings of satiety 30 slower digestion rate compared to other macronutrients Adequate protein intake while in a caloric deficit, either through the use of GLP-1 medications or adhering to a lower calorie diet, is essential for helping to protect lean body mass
Reported positive in December 2025, first Phase 3 readout of the program
